Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15233281rdf:typepubmed:Citationlld:pubmed
pubmed-article:15233281lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:15233281lifeskim:mentionsumls-concept:C0026850lld:lifeskim
pubmed-article:15233281lifeskim:mentionsumls-concept:C0033325lld:lifeskim
pubmed-article:15233281lifeskim:mentionsumls-concept:C0439849lld:lifeskim
pubmed-article:15233281lifeskim:mentionsumls-concept:C1522564lld:lifeskim
pubmed-article:15233281lifeskim:mentionsumls-concept:C1306673lld:lifeskim
pubmed-article:15233281lifeskim:mentionsumls-concept:C0016441lld:lifeskim
pubmed-article:15233281lifeskim:mentionsumls-concept:C0205210lld:lifeskim
pubmed-article:15233281lifeskim:mentionsumls-concept:C1883709lld:lifeskim
pubmed-article:15233281pubmed:issue3lld:pubmed
pubmed-article:15233281pubmed:dateCreated2004-7-5lld:pubmed
pubmed-article:15233281pubmed:abstractTextThe evaluation of myocardial damage by [123I] 15-(p-iodophenyl)-3-(R,S)-methylpentadecanoic acid (BMIPP) imaging, which represents free fatty acid metabolism, has not been reported in patients with Duchenne-type muscular dystrophy (DMD). To date, the relationship between clinical stage, prognosis and myocardial damage has not been evaluated by radionuclear cardiac imaging. The main goal of this study was to elucidate the relationship of quantitative indices of myocardial damage obtained by radionuclear cardiac imaging ([201Tl] and [123I] BMIPP) to clinical stage and incidence of severe cardiac events in patients with Duchenne-type muscular dystrophy (DMD).lld:pubmed
pubmed-article:15233281pubmed:languageenglld:pubmed
pubmed-article:15233281pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15233281pubmed:citationSubsetIMlld:pubmed
pubmed-article:15233281pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15233281pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15233281pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15233281pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15233281pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15233281pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15233281pubmed:statusMEDLINElld:pubmed
pubmed-article:15233281pubmed:monthMaylld:pubmed
pubmed-article:15233281pubmed:issn0914-7187lld:pubmed
pubmed-article:15233281pubmed:authorpubmed-author:OhyanagiMitsu...lld:pubmed
pubmed-article:15233281pubmed:authorpubmed-author:IwasakiTadaak...lld:pubmed
pubmed-article:15233281pubmed:authorpubmed-author:NaruseHitoshi...lld:pubmed
pubmed-article:15233281pubmed:authorpubmed-author:MiyagiJunkoJlld:pubmed
pubmed-article:15233281pubmed:authorpubmed-author:JinnaiKenjiKlld:pubmed
pubmed-article:15233281pubmed:authorpubmed-author:AriiTohruTlld:pubmed
pubmed-article:15233281pubmed:issnTypePrintlld:pubmed
pubmed-article:15233281pubmed:volume18lld:pubmed
pubmed-article:15233281pubmed:ownerNLMlld:pubmed
pubmed-article:15233281pubmed:authorsCompleteYlld:pubmed
pubmed-article:15233281pubmed:pagination203-8lld:pubmed
pubmed-article:15233281pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:15233281pubmed:meshHeadingpubmed-meshheading:15233281...lld:pubmed
pubmed-article:15233281pubmed:meshHeadingpubmed-meshheading:15233281...lld:pubmed
pubmed-article:15233281pubmed:meshHeadingpubmed-meshheading:15233281...lld:pubmed
pubmed-article:15233281pubmed:meshHeadingpubmed-meshheading:15233281...lld:pubmed
pubmed-article:15233281pubmed:meshHeadingpubmed-meshheading:15233281...lld:pubmed
pubmed-article:15233281pubmed:meshHeadingpubmed-meshheading:15233281...lld:pubmed
pubmed-article:15233281pubmed:meshHeadingpubmed-meshheading:15233281...lld:pubmed
pubmed-article:15233281pubmed:meshHeadingpubmed-meshheading:15233281...lld:pubmed
pubmed-article:15233281pubmed:meshHeadingpubmed-meshheading:15233281...lld:pubmed
pubmed-article:15233281pubmed:meshHeadingpubmed-meshheading:15233281...lld:pubmed
pubmed-article:15233281pubmed:meshHeadingpubmed-meshheading:15233281...lld:pubmed
pubmed-article:15233281pubmed:meshHeadingpubmed-meshheading:15233281...lld:pubmed
pubmed-article:15233281pubmed:meshHeadingpubmed-meshheading:15233281...lld:pubmed
pubmed-article:15233281pubmed:meshHeadingpubmed-meshheading:15233281...lld:pubmed
pubmed-article:15233281pubmed:meshHeadingpubmed-meshheading:15233281...lld:pubmed
pubmed-article:15233281pubmed:meshHeadingpubmed-meshheading:15233281...lld:pubmed
pubmed-article:15233281pubmed:meshHeadingpubmed-meshheading:15233281...lld:pubmed
pubmed-article:15233281pubmed:meshHeadingpubmed-meshheading:15233281...lld:pubmed
pubmed-article:15233281pubmed:meshHeadingpubmed-meshheading:15233281...lld:pubmed
pubmed-article:15233281pubmed:year2004lld:pubmed
pubmed-article:15233281pubmed:articleTitleThe relationship between clinical stage, prognosis and myocardial damage in patients with Duchenne-type muscular dystrophy: five-year follow-up study.lld:pubmed
pubmed-article:15233281pubmed:affiliationDepartment of Cardiology, Takarazuka Municipal Hospital, Takarazuka, Japan. Nallure@aol.comlld:pubmed
pubmed-article:15233281pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15233281pubmed:publicationTypeClinical Triallld:pubmed